



30th September 2015

National Stock Exchange,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East), Mumbai
400051

GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +022 2495 9595
Fax No: +022 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

Dear Sir,

Sub: Intimation under Clause 36 – regarding GSK and Novartis deal

Further to our letter dated 12th February, 2015 regarding the aforesaid subject, we wish to inform you that the Company has completed its transaction with Novartis Healthcare Pvt. Ltd. ('Novartis India') today whereby the Company has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis India.

This follows a global transaction between GlaxoSmithKline plc, UK(GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.

The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK's vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.

The above is for your information. Please take the above on your records.

Thanking you,

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Company Secretary
ACS No. 11026